INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10536939	
Filing Date		2006-04-11	
First Named Inventor Chris		tophe Revirron	
Art Unit		1617	
Examiner Name	Rama	achandran, Umamaheswari	
Attorney Docket Number		05-403	

/U.R./	1	Bousquet J, Van Cauwenberge P, Khalraev N. Allergic rhinitis and its impact on asthma. J. Allergy Clin Immunol. 2001;108(5 Suppl):S147-334	
	2	International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy. 1994;49(19 Suppl):1-34	
	3	Dykewicz MS. 7.Rhinitis and sinusitis. J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S520-9.	
	4	Dykewicz MS, Fineman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol. 1998;81(5Pt2):463-8.	
	5	Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allerglogy and Clinical Immunology. Allergy. 2000 Feb;55 (2):116-34.	
	6	Walls RS, Heddle RJ, Tang ML, Basger BJ, Solley GO, Yeo GT. Optimising the mangement of allergic rhinitis: an Australian perspective. Med J. Aust. 2005 Jan 3;182(1):463-8.	
	7	Bucholtz GA, Lockey RF, Wunderlin RP, Binford LR, Stablein JJ, Serbousek D, et al. A three-year aerobiologic pollen survey of the Tampa Bay area, Florida. Ann Allergy. 1991;67(5):534-40.	
	8	D'Amato G, Lobefalo G. Allergenic pollens in the southern Mediterranean area. J Allergy Clin Immunol. 1989;83 (1):116-22.	
	9	Bousquet J, Ammesi-Maesano I, Carat F; Leger D, Rugina M, Pribil C, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005Jun;35(6):728-32.	
	10	Bauchau V, Durham SR, Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004 Nov;24 (5):758-64.	
V	11	Arbes SJ, Jr., Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005 Aug;116(2): 377-83.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10536939
Filing Date		2006-04-11
First Named Inventor Chri		tophe Revirron
Art Unit		1617
Examiner Name	Rama	achandran, Umamaheswari
Attorney Docket Number		05-403

/U.I	R./	12	Sibbald B, Rink E, Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax. 1991;46(12):895-901.	
		13	Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, et al. Seasonal and Perennial allergic rhinitis: is this classification adherent to real life? Allergy. 2005 Jul;60(7):882-7.	
		14	Connell JT. Quantitative intranasal pollen challenges. 3. The priming effect in allergic rhinitis. J Allergy. 1969;43 (1):33-44.	
		15	Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol. 1989;84(4 Pt 1):492-501.	
			Juliusson S, Bende M. Priming effect of a birch pollen season studied with laser Doppler flowmetry in patients with allergic rhinitis. Clin Allergy. 1988;18(6):615-8.	
		17	Knani J, Campbell A, Enander I, Peterson CG, Michel FB, Bousquet J. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol. 1992;90(6 Pt 1):880-9.	
		18	Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, et al. Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol. 1995;96(6 Pt 1):971-9.	
		19	Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica G, et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immuno. 1999;104:in press.	
		20	Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005 Mar;60(3):350-3.	
		21	Demoly P, Allaert FA, Lecasble M, Bousquet J. Validation of the classification of ARIA (allergic rhinitis and its impact on asthma). Allergy. 2003 Jul;58(7):672-5.	
	/	22	Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med. 2000 Oct:162(4 Pt 1):1391-6.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10536939	
Filing Date		2006-04-11	
First Named Inventor	Chris	tophe Revirron	
Art Unit		1617	
Examiner Name	Rama	achandran, Umamaheswari	
Attorney Docket Number		05-403	

/U	l.R./	23	Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Stratus Questionnaire. J Allergy Clin Immunol 1994;94(2 Pt 1):182-8.		in patients with Allergy Clin Immunol.			
		24	Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994:93(2):413-23.					
		25	Roberts G, Hurley C, Lack G. Development of a quality-of-life assessment for the allergic child or teenager with multisystem allergic disease. J Allergy Clin Immunol. 2003 Mar;111(3):491-7.					
		26	McNicholas WT, Tarlo S, Cole P, Zamel N, Rutherford R, Griffin D, et al. Obstructive apneas during sleep in patietns with seasonal allergic rhinitis. Am Rev Respir Dis. 1982;126(4):625-8.					
		27	Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, et al. Levocetrizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol. 2004 Oct;114(4):838-44.					
		28	William E. Berger, et al. Saftey and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Annals of Allergy, Asthma, & Immunology.2002 Nov;89:485-91.					
	Eli O. Meltzer, et al. Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic Rhinitis. Clin Drug Invest.2001; 21(1):25-32.							
\	/	30	F. Estelle R. Simons, MD, et al. Efficacy and saftey of desloratedine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol.2003 Mar; 111(3):617-22.					
If you wish to add additional non-patent literature document citation information please click the Add button								
EXAMINER SIGNATURE								
Exa	Examiner Signature /Umamaheswari Ramachandran/ Date Considered 12/28/2007							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								